Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Urogen Pharma ( (URGN) ).
On January 2025, UroGen Pharma Ltd. presented an investor update highlighting the potential of their proprietary RTGel® technology platform to transform urothelial cancer treatment paradigms. JELMYTO is already FDA-approved for treating low-grade upper tract urothelial carcinoma (LG-UTUC) non-surgically. UGN-102, pending approval, aims to become the standard of care for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) with a significant market opportunity. The company also discussed ongoing and planned studies for UGN-301 in high-grade non-muscle invasive bladder cancer (HG-NMIBC) and its expansion into immuno-oncology. UroGen’s strategic focus includes advancing pre-commercial activities for UGN-102, extending leadership in unmet needs for urothelial cancers, and ensuring sustainable growth.
More about Urogen Pharma
UroGen Pharma Ltd. operates in the pharmaceutical industry focusing on developing innovative medicines for urothelial cancers. The company specializes in proprietary technology aimed at enhancing proven and novel therapies, aligning them with urological practices. Their notable products include JELMYTO, UGN-102, UGN-103, and UGN-301, with ongoing research and clinical trials to improve treatment options for various forms of urothelial cancer.
YTD Price Performance: -4.86%
Average Trading Volume: 478,065
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $432.1M
For a thorough assessment of URGN stock, go to TipRanks’ Stock Analysis page.